drugset / Trial / NCT05480657
Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.
Timeline
- Start
- 2022-09-30
- Primary completion
- 2024-08
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Isolated cadaveric islet cells | Cell therapy | — | Other |
| Subject | Tegoprubart | Monoclonal antibody | — | Intravenous |